Mayo Clinic LabsA Family’s Journey with an Ultra-Rare Disease: Isabel the Incredible

Hereditary TTP affects roughly one in a million worldwide, and diagnostic delays remain the norm. Recombinant ADAMTS13 now enables home-based weekly infusions, shifting the management burden away from infusion centers.

Clinical Considerations

• Neonatal presentation can be subtle: low Apgar, poor color, breathing irregularity often labeled idiopathic before hereditary TTP surfaces
• ADAMTS13 enzyme deficiency drives microvascular thrombosis, platelet consumption, and multi-organ involvement including kidneys and brain
• Quarterly ADAMTS13 level and inhibitor monitoring catches treatment response gaps and complications early
• Home infusion eligibility depends on caregiver clinical training and stable enzyme levels, not pediatric age alone

Practice Applications

• Consider hereditary TTP in pediatric patients with unexplained anemia, thrombocytopenia, and recurrent illness
• Integrate ADAMTS13 activity and inhibitor testing into the workup before labeling presentations idiopathic
• Recognize recombinant ADAMTS13 as standard replacement therapy for confirmed hereditary cases
• Monitor treatment burden and home infusion feasibility as part of long-term care planning

More in Rare Conditions & Diseases